|
Sign In to gain access to subscriptions and/or personal tools.
|
Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection
Emanuel F. Petricoin
FDA-NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA, petricoin{at}cber.fda.gov
Vinodh Rajapaske
FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
Eugene H. Herman
Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA
Ali M. Arekani
FDA-NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
Sally Ross
FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
Donald Johann
FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
Alan Knapton
Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA
J. Zhang
Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA
Ben A. Hitt
Correlogic Systems, Inc., Bethesda, Maryland, USA
Thomas P. Conrads
NCI Biomedical Proteomics Program, Analytical Chemistry Laboratory, Mass Spectrometry Center, SAIC Frederick, Inc., SAIC-NCI, Frederick, Maryland, USA
Timothy D. Veenstra
NCI Biomedical Proteomics Program, Analytical Chemistry Laboratory, Mass Spectrometry Center, SAIC Frederick, Inc., SAIC-NCI, Frederick, Maryland, USA
Lance A. Liotta
FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
Frank D. Sistare
Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA
Proteomics is more than just generating lists of proteins that increase or decrease in expression as a cause or consequence of pathology. The goal should be to characterize the information flow through the intercellular protein circuitry which communicates with the extracellular microenvironment and then ultimately to the serum/plasma macroenvironment. The nature of this information can be a cause, or a consequence, of disease and toxicity based processes as cascades of reinforcing information percolate through the system and become reflected in changing proteomic information content of the circulation. Serum Proteomic Pattern Diagnostics is a new type of proteomic platform in which patterns of proteomic signatures from high dimensional mass spectrometry data are used as a diagnostic classifier. While this approach has shown tremendous promise in early detection of cancers, detection of drug-induced toxicity may also be possible with this same technology. Analysis of serum from rat models of anthracycline and anthracenedione induced cardiotoxicity indicate the potential clinical utility of diagnostic proteomic patterns where low molecular weight peptides and protein fragments may have higher accuracy than traditional biomarkers of cardiotoxicity such as troponins. These fragments may one day be harvested by circulating nanoparticles designed to absorb, enrich and amplify the diagnostic biomarker repertoire generated even at the critical initial stages of toxicity.
Key Words: Mass spectrometry • toxicoproteomics • proteomics • cardiotoxicity • patterns • nanotechnology.
References
- Adam, B.L., Qu, Y., Davis, J.W., Ward, M.D., Clements, M.A., Cazares, L.H., Semmes, O.J., Schellhammer, P.F., Yasui, Y., Feng, Z., and Wright, Jr. G.L. (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62(13), 3609—14.[Abstract/Free Full Text]
- Alderton, P.M., Gross, J., and Green, M.D. (1992). Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529). Cancer Res 52(1), 194—201.[Abstract/Free Full Text]
- Anderson, N.L., and Anderson, N.G. (2002). The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 11, 845— 67.
- Bristow, M.R., Mason, J.W., Billingham, M.E., and Daniels, S.R. (1981). Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102, 709—18.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Cojocel, C., Maita, K., Baumann, K., and Hook, J.B. (1984). Renal processing of low molecular weight proteins. Pflugers Arch 401(4), 333—9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Conrads, T.P., Zhou, M., Petricoin, E.F. III, Liotta, L., and Veenstra, T.D. (2003). Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn 3(4), 411—20.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ewer, M.S., Gibbs, H.R., Swafford, J., and Benjamin, R.S. (1999). Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26(suppl. 12), 96—101.[Web of Science][Medline]
[Order article via Infotrieve]
- Hasinoff, B.B., Hellmann, K., Herman, E.H., and Ferrans, V.J. (1998). Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5(1), 1—28.[Web of Science][Medline]
[Order article via Infotrieve]
- Hasinoff, B.B., Schnabl, K.L., Marusak, R.A., Patel, D., and Huebner, E. (2003). Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 3(2), 89—99.[CrossRef][Medline]
[Order article via Infotrieve]
- Herman, E.H., and Ferrans, V.J. (1998). Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol 25(Suppl 10), 15—21.[Web of Science][Medline]
[Order article via Infotrieve]
- Herman, E.H., Zhang, J., Rifai, N., Lipshultz, S.E., Hasinoff, B.B., Chadwick, D.P., Knapton, A., Chai, J., and Ferrans, V.J. (2001). The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 48(4), 297—304.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hingorani, S.R., Emanuel, F., Petricoin, E.F., III, Maitra, A., Rajapakse, V., King, C., Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., Kawaguchi, Y., Zhou, Y., Johann, D., Liotta, L.A., Crawford, H.C., Putt, M.E., Jacks, T., Konieczny, S.F., Wright, C.E., Hruban, R.E., Lowry, A.M., and Tuveson D. A. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 10, 6—21.
- Holland, J. H., ed. (1994). Adaptation in Natural and Artificial Systems: an Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence, 3rd ed., MIT Press Cambridge, Massachusetts.
- Kantor, A.B. (2002). Comprehensive phenotyping and biological marker discovery. Dis Markers 18(2), 91—7.[Web of Science][Medline]
[Order article via Infotrieve]
- Kohonen, T. (1982). Self-organizing formation of topologically correct feature maps. Biol Cybernetics 43, 59—69.[CrossRef][Web of Science]
- Kohonen, T. (1990). The self-organizing map. Proc IEEE 78, 1464—80.[CrossRef]
- Lambertenghi-Deliliers G., Zanon, P.L., Pozzoli, E.F., and Bellini, O. (1976) Myocardial injury induced by a single dose of adriamycin: an electron microscopic study. Tumor 62, 517—28.
- Li, J., Zhang, Z., Rosenzweig, J., Wang, Y.Y., and Chan, D.W. (2002). Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48(8), 1296—304.[Abstract/Free Full Text]
- Liotta, L.A., Ferrari, M., and Petricoin, E. (2003). Clinical proteomics: written in blood. Nature 425, 905.[CrossRef][Medline]
[Order article via Infotrieve]
- Maack, T. (1975). Renal handling of low molecular weight proteins. Am J Med 58(1), 57—64.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- McDonald, W.H., and Yates, J.R., III. (2002). Shotgun proteomics and biomarker discovery. Dis Markers 18(2), 99—105.[Web of Science][Medline]
[Order article via Infotrieve]
- Mehta, A., Ross, S., Lowenthal, M.S., Fusaro, V. Fishman, D.A., Petricoin, E.F., and Liotta, L.A. (2003). Biomarker amplification by serum carrier protein binding. Disease Markers 19, 1—10.[Web of Science][Medline]
[Order article via Infotrieve]
- Petricoin, E.F., III, Ardekani, A.M., Hitt, B.A., Levine, P.J., Fusaro, V.A., Steinberg, S.M., Mills, G.B., Simone, C., Fishman, D.A., Kohn, E.C., and Liotta, L.A. (2002a). Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572—7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Petricoin, E., III, and Liotta, L.A. (2003a). Counterpoint: the vision for a new diagnostic paradigm. Clin Chem 49(8), 1276—1278.[Free Full Text]
- Petricoin, E.F., and Liotta, L.A. (2003b). Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem 49(4), 533—4.[Free Full Text]
- Petricoin, E.F., III, Mills, G.B., Kohn, E.S., Liotta, L.A. (2002b). Proteomic patterns in serum and identification of ovarian cancer [Reply]. Lancet 360, 170—1.[Web of Science][Medline]
[Order article via Infotrieve]
- Petricoin, E.F., III, Ornstein, D.K., Paweletz, C.P., Ardekani, A., Hackett, P.S., Hitt, B.A., Velassco, A., Trucco, C., Wiegand, L., Wood, K., Simone, C.B., Levine, P.J., Linehan, W.M., Emmert-Buck, M.R., Steinberg, S.M., Kohn, E.C., and Liotta, L.A. (2002c). Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94(20), 1576—8.[Abstract/Free Full Text]
- Tirumalai, R.S., Chan, K.C., Prieto, D.A., Issaq, H.J., Conrads, T.P., and Veenstra, T.D. (2003). Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2(10), 1096—103. [Epub 2003 Aug 13].[Abstract/Free Full Text]
- Tou, J. T., and Gonzalez, R., eds. (1974). Pattern Classification by Distance Functions. In Pattern Recognition Principles, Reodina MA: Addison Weley Publishing Comapny. New York.
- Ward, J.B. Jr., and Henderson, R.E. (1996). Identification of needs in biomarker research. Environ Health Perspect 104(Suppl. 5), 895—900.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Zhang, J., Herman, E.H., and Ferrans, V.J. (1993). Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am J Pathol 142(6), 1916—26.[Abstract]
- Zhang, J., Herman, E.H., Knapton, A., Chadwick, D.P., Whitehurst, V.E., Koerner, J.E., Papoian, T., Ferrans, V.J., and Sistare, F.D. (2002). SK&F 95654-Induced acute cardiovascular toxicity in Sprague-Dawley rats— histopathologic, electron microscopic, and immunohistochemical studies. Toxicol Pathol 30(1), 28—40.[Abstract/Free Full Text]
Toxicologic Pathology, Vol. 32, No. 1 suppl,
122-130 (2004)
DOI: 10.1080/01926230490426516
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Gao, R. D. Holland, and L.-R. Yu
Quantitative proteomics for drug toxicity
Brief Funct Genomic Proteomic,
April 7, 2009;
(2009)
elp006v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Merrick
The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research
Brief Funct Genomic Proteomic,
January 1, 2008;
7(1):
35 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
